Press Releases

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong returns for the six months ended 31 December 2009. The excellent performance from the South Africa business underpinned the results. Group Performance: Group revenue increased by 10 percent to R4.576 billion (R4.142 billion). Group operating profit increased by 16 percent to R1.314 billion (R1.136 billion). Group headline earnings per share (HEPS) from continuing operations increased by 27 percent to 242.3 cents (193.8 cents). Group profit after tax from continuing operations increased by 31 percent to R889 million (R690 million). Stephen Saad, Aspen Group Chief Executive said “the excellent performance recorded by the South African business was driven by robust volume growth and margin improvements. Revenue growth in the international business is attributed to gains from Global brands, the Asia Pacific domestic brands, the oncology business and from the Glaxosmithkline (“GSK”) transactions.” Completion of the GSK transactions: With effect from 1 December 2009, Aspen completed a series of strategic, interdependent transactions with GSK (“the GSK transactions”) which had been announced on 12 May 2009. The GSK transactions comprise: The acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa; The formation of a collaboration agreement between Aspen and GSK in relation to the marketing and selling of prescription pharmaceuticals in sub-Saharan Africa; The acquisition by Aspen Global of eight specialist branded products (Alkeran, Leukeran, Purinethol, Kemadrin, Lanvis, Myleran, Septrin and Trandate) for worldwide distribution; The acquisition of GSK’s manufacturing facility in Bad Oldesloe, Germany; and The issue by Aspen of 68.5 million ordinary shares to GSK at R66.80 per share amounting to a total value of R4.576 billion. South African Business: The South African business maintained its leadership position across the private and public sectors of the pharmaceutical market and grew revenue by 23% to R2.550 billion. Operating profit from the South African business increased from R484 million to R806 million. Other operating income includes an amount of R145 million received as insurance compensation for loss of profits and asset replacement arising from the explosion which occurred at the Nutritionals Facility in August 2009. Profit margins improved after the contractions in the previous two years caused by a weak Rand and delays in the passing of an increase to the SEP in the private pharmaceutical market. The pharmaceutical division led growth in the South African business with revenue rising 30% to R1.975 billion. Aspen’s robust growth in pharmaceuticals was characterised by volume gains across the extensive product offering. . The consumer division increased revenue by 6% to R575 million. This credible performance was recorded despite the prevailing recessionary effects in the retail environment as well as the negative impact on sales of infant milk formula due to the temporary unavailability of certain products resulting from the damage incurred at the Nutritionals Facility. The Group’s South African manufacturing facilities achieved impressive efficiency gains as the benefits of the significant capital expenditure programme of the last few years begin to be realised. The second Oral Solid Dose Facility and the eye-drop suite of the Sterile Facility commenced production at the Port Elizabeth-based site. The hormonal suite of the Sterile Facility is scheduled to commence commercial production before the end of the 2010 financial year. Capital projects in progress include the addition of increased tableting capacity and the installation of suppository and dutch medicines manufacturing at the East London site. Reconstruction of the drying tower at the Nutritionals Facility is well advanced and production is expected to recommence within the next six months. Sub-Saharan Africa Business: In anticipation of the future materiality of this region, Aspen has established a separate management and reporting structure for the sub-Saharan Africa business. Included in this business segment are exports into sub-Saharan Africa from South Africa, the Shelys Africa business based in East Africa and the GSK Aspen Healthcare for Africa collaboration. Revenue from the sub-Saharan Africa business declined from R464 million in the prior period to R279 million and operating profit decreased from R99 million to R45 million. The steep reversal in results was due to export business lost through the genericisation of patented ARV molecules marketed by Aspen. Sales by Shelys Africa were also reduced as this business shed low margin tenders in accordance with the strategic plan for the operation, without affecting profits. GSK Aspen Healthcare for African began operations on 1 December 2009 and will in future be the most material contributor to the region. International Business: Revenue from the international business increased by 12% to R1.797 billion. Gains from Global brands, the Asia Pacific domestic brands, the oncology business and the additional revenue from the GSK transactions were partially offset by reversals in Latin America. Operating profit declined from R554 million to R463 million largely as a consequence of losses in Latin America and a strengthening of the Rand against most of the underlying trading currencies. An 18% increase in revenue to R824 million from the Global brands is largely attributable to revenue from Eltroxin, Lanoxin, Imuran and Zyloric, which were acquired with effect from 30 June 2008. Worldwide sales from these four Global brands achieved double-digit growth in United States Dollars (“USD”). The balance of the growth in the Global brands came from the addition of Aggrastat and the introduction of the eight products acquired from 1 December 2009 under the GSK transactions. The Asia Pacific domestic brands increased revenue by 8% to R522 million. This business, largely Australian based, again performed well considering the downward pricing pressure being experienced in this territory. Aspen has exercised its call on the remaining 49% shareholding in the Latin American businesses. Given that Aspen already has full rights to the economic performance of these businesses there is no further purchase consideration required for the acquisition of this remaining shareholding. Revenue from domestic brands in Latin America declined by 15% to R345 million. The primary underperformer was the Brazilian business, Aspen’s largest operation in the region. Aspen has assumed full operational control of the Brazilian business and has implemented a

Johannesburg – JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2009. Prevailing global economic conditions did little to deter the strength of the Group’s performance, with the South African and Australian businesses continuing to perform well. Aspen’s international expansions resulted in substantially increased contributions from the offshore businesses, delivering an operating profit of R1.076 billion. GROUP PERFORMANCE: Group revenue increased by 80% to R8,450 billion (R4.881 billion). Group operating profit improved by 82% to R2,183 billion (R1.298 billion). Group headline earnings per share (HEPS) grew by 68% to 389.4 cents (231.3 cents). Stephen Saad, Aspen Group Chief Executive said, “The Group’s international operations delivered positive results, delivering an increased contribution to earnings of 47% up from 15% last year. The South African business has achieved excellent growth and has increased its contribution to earnings by 14%, while retaining its position as the market leader in the pharmaceutical sector and improving its market share in all market segments. SOUTH AFRICAN OPERATIONS RETAIN MARKET LEADERSHIP Aspen’s South African business remains the market leader in the total private pharmaceutical market, the private generic market, the public sector pharmaceutical market and in the supply of anti-retrovirals (ARVs) to both the private and the public sectors. Campbell Belman’s independent Confidence Standing Survey of 42 over-the-counter (OTC) companies by 146 top retail pharmacies, again ranked Aspen as the top OTC company for the fourth time in the past six years. The South African business increased revenue by 30% to R4,868 billion amidst difficult trading conditions. Notwithstanding margin pressure, EBITA grew by R149 million to R1,208 billion. Restrictive factors such as accelerated raw material prices, production inflation and legislated fixed Single Exit Prices (SEP) impacted returns in the first half. A margin improvement was seen in the final quarter as a consequence of the Department of Health’s 13.2% increase in SEP in February 2009 and the implementation of the state tender price adjustment mechanism. An impressive performance was delivered by the pharmaceutical division, with revenue increasing by 34% to R3,767 billion. These results were driven by organic volume growth and the successful launches of Truvada, Viread, Vectoryl and Aspen Efavirenz. The consumer division’s 16% revenue increase to R1.101 billion was positive given the depressed retail sector. Leading brands such as Lennon Dutch Medicines, Infacare, S26, Guronsan C and Hamburg Tea delivered a credible performance. Prospects for the ophthalmic portfolio were enhanced with the addition of Eye-gene and Murine, while Melegi, a new infant milk formulation was launched and exported into selected African countries. Additional oral solid dose (OSD) manufacturing capacity was realised in Port Elizabeth with the completion of more packing lines. This provided relief to production pressure driven by unprecedented public sector demand. The new OSD tabletting production plant, presently undergoing validation, will provide further capacity before the end of 2009. The Sterile Facility’s eye-drop suite has commenced exporting Clear Eyes and Murine to Prestige Brands in the United States, while trials have been initiated in the hormonal suite. An explosion in the drying tower at Aspen’s Nutritionals Facility on 18 August 2009 caused extensive damage to that section of the production site. Blending and packing areas were unaffected and production in the drying tower should recommence before the end of the 2010 financial year. Contingency plans have been implemented to ensure continued supply of infant milk formulations to the market. INTERNATIONAL OPERATIONS DELIVER PLEASING RETURNS Over the past 18 months, the Group’s international expansion has been driven by acquisitions in Brazil, Mexico, Venezuela, Tanzania, Kenya and Uganda. With effect from 30 June 2008, the Group’s intellectual property portfolio in international markets was significantly enhanced by the acquisition of four globally branded products, Eltroxin, Lanoxin, Imuran and Zyloric from GSK for GBP 170 million. The global product range was also supplemented by two licensing transactions for branded products with US-based Iroko Pharmaceuticals. Aspen products are now distributed to more than 100 countries across the world. This expansion has resulted in a substantial increase in the contribution from international operations to the Group. Revenue of R3,869 billion was achieved, up from R1,123 billion and EBITA from continuing operations was R1,071 billion, up from R209 million. The global brands comprised R1.438 billion of revenue. Transition of distribution arrangements for the global brands to the Aspen network has already commenced, with the remainder of the transition scheduled in the 2010 financial year. Aspen Australia’s positive performance yielded a 29% increase in revenue to R915 million, despite legislated price cuts. These results were driven by effective product promotions and expanded product offerings. Aspen’s Latin American business recorded revenue of R841 million, but the potential of this territory remains to be realised. Initiatives receiving active attention include the strengthening of management, increasing representation in the private sector, launching new products and establishing a medium-term product pipeline. The Group’s East African business reported revenue of R373 million in a year in which political unrest in Kenya had a negative impact upon trade. Aspen disposed of its 50% shareholding in the ARV active pharmaceutical ingredient manufacturer, Astrix, for USD 39 million, with effect from 31 May 2009. GSK TRANSACTIONS On 12 May 2009 Aspen announced that it had agreed terms on a series of strategic interdependent transactions (“the GSK transactions”) with GSK, being: the acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa; the formation of a collaboration arrangement between Aspen and GSK in relation to the marketing and selling of prescription pharmaceuticals in sub-Saharan Africa; the acquisition by Aspen Global of eight specialist branded products (Alkeran, Leukeran, Purinethol, Kemadrin, Lanvis, Myleran, Septrin and Trandate) for worldwide distribution; the acquisition of GSK’s manufacturing facility in Bad Oldesloe, Germany; and Aspen to issue 68.5 million shares to GSK as consideration for the transactions. The completion of the transactions was subject to the fulfillment of a number of conditions precedent. Certain of these conditions precedent have now been fulfilled, amongst these the approval of the South African Competition Authorities

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded strong revenue growth for the six months ended 31 December 2008. The positive returns were stimulated by Aspen’s recently expanded international operations. The existing businesses in South Africa and Australia have once again recorded sustained growth. Revenue increased by 91 percent to R4 264 million (R2 230 million). Operating profit increased by 84 percent to R1 163 million (R633.8 million). Headline earnings per share (HEPS) increased by 77 percent to 193.8 cents (109.6 cents). Increase in earnings per share (“EPS”) was lower than HEPS at 54 percent to 192.5 cents (125.0 cents) owing to the inclusion of non-recurring capital profits in the determination of EPS in the prior year. Stephen Saad, Aspen Group Chief Executive said “we are pleased to have delivered such positive results in a challenging operating environment. The Group’s international businesses have been the primary growth driver for the period under review. For the first time, profits from offshore operations exceeded those of the South African business. Aspen’s local presence remains strong with increased market share in all pharmaceutical categories. The Group retaining its ranking as the leading pharmaceutical company in the South African private and public market sectors.” SOUTH AFRICAN OPERATIONS Aspen’s South African business increased revenue by 32% to R2 331 million (R1 771 million). This growth was led by the pharmaceutical division which grew sales by 35% to R1 789 million driven by a substantial increase in volumes and a positive performance from recently launched products such as Truvada™, Viread™, Vectoryl™ and Aspen effavirenz. Growth in earnings before interest, tax and amortisation (“EBITA”) was limited to 10% at R586 million owing to a change in product mix due to a lower margin in public sector products, higher commodity prices, inflationary pressures and fixed pricing under both the Single Exit Pricing (“SEP”) regulations and the State Tender awards. The over-the-counter (“OTC”) division delivered good results with leading brands such as Flusin™, Lenadol® and Sinuclear® contributing positively. Aspen has successfully launched replacement products under its major slimming brands Thinz®, Leanor™ and Slenz® due to the South African Medicines Control Council’s (“MCC”) banning of d-norpseudoephedrine, the active ingredient in slimming preparations. Household brands such as Lennon Dutch Medicines®, Woodwards™ Gripewater and Guronsan® C supported the consumer division’s 22% revenue growth which is a pleasing return given the pressure felt in the retail sector. Laxative brands are being re-developed following the MCC’s withdrawal of phenolphthalein-containing products. Excellent returns were recorded by Aspen Nutritionals. The existing portfolio of infant nutritional brands such as Infacare®, S26® and SMA® was enhanced with the launch of Melegi™, which is exported to selected African countries. High levels of productivity were achieved at Aspen’s manufacturing facilities in order to respond to growing volumes. Continued investment in manufacturing will unlock additional capacity at the Port Elizabeth site. Commercialisation of eye-drops at Aspen’s Sterile Facility is expected to take place before year-end. Aspen will supply eye-drops to the USA market under a contract with Prestige Incorporated. INTERNATIONAL OPERATIONS Contributions from Aspen’s international operations increased sharply, following the Group’s recent expansion into more than 100 new markets. An increase in revenue was recorded at R1 934 million (R460 million) while EBITA rose to R630 million (R101 million). The Group also strengthened its intellectual property portfolio with the acquisition of Eltroxin™, Lanoxin™, Imuran™ and Zyloric™ from GlaxoSmithKline (“GSK”) and licensing deals with US-based Iroko Pharmaceuticals for the distribution of products into emerging markets. Revenue from global brands amounted to R696 million. Aspen Australia recorded sustained growth through the expansion of its product offering, thereby increasing revenue by 55% to R484 million (R311.7 million). Group revenue from the Latin American operations comprised 10% with sales of R408 million. The primary contributor was Brazil’s Cellofarm accounting for R330 million, with the Mexican and Venezuelan companies contributing the balance. Strategies are in place to grow the Brazilian market share, with focus being re-directed to the private sector. A brand development strategy has been initiated and 150 experienced sales representatives have been recruited for the fulfilment thereof. Construction of the manufacturing facilities in Campos, Brazil has been completed. The Brazilian authorities have accredited the Penem Facility thereby enabling the commencement of commercial production. The Penicillin Facility is awaiting final regulatory approval. Shelys, the Group’s business in East Africa, recorded revenue of R200 million in Tanzania, Kenya and Uganda. The OTC Manufacturing Facility under construction in Nairobi, is due for completion before the end of 2009. PROSPECTS Growth in South African volumes is expected to remain buoyant during the second half of the year. The 13.2% increase in SEP will offset the impact of higher supply costs. Despite trading difficulties in the retail sector, it is anticipated that the successful strategies implemented by the consumer division will yield favourable results. Additional production capacity will be realised during the forthcoming calendar year when Aspen’s three major capital projects in Port Elizabeth, valued at R1 billion, are completed. The solid dosage manufacturing and packing capabilities will cater for anticipated growth in demand from domestic and international markets. The Sterile Facility will provide Aspen with production capabilities in injectables, hormonal injectables and eye-drops for all major international markets. It is expected that the international businesses will provide significant impetus to the Group’s growth. Cognisance should be taken of influencing factors most notably global currency exposures and world market volatility. The product pipeline for the international business remains a major focus area with benefits expected to become apparent in the next two to three years. The Bangalore Oncology Facility has been accredited by the Australian Therapeutic Goods Association and commercial production is scheduled to commence in 2010. The disposal of Aspen’s 50% shareholding in Astrix remains subject to fulfilment of conditions precedent. Aspen’s performance in the first half of this financial year has shown resilience and strategies have been implemented which are designed to add to the Group’s performance in future years.